MDP-CRO announces first patient enrollment for AS Kevelt

MDP-CRO announces first patient enrollment for AS Kevelt in Phase II Clinical Trial of Sodium Cridanimod in Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma
Tallinn, Estonia – 19 January 2015 – AS Kevelt, a leading pharmaceutical company in the development of anticancer therapies in the Baltic, today announced the first patient has been enrolled in the Phase II clinical trial of Sodium Cridanimod (Virexxa®) in Patients with Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma.

AS Kevelt comments:

We are very pleased to begin this important trial and are grateful to Dr. Zigmund Gedrevich and his team at Minsk City Clinical Oncology Dispensary (Minsk, Belarus) for making this happen” said Allan Ahtloo, a Member of the Board of AS Kevelt. “This Phase II trial will provide critical information about how we approach treatment for patients with this difficult diagnosis.

The clinical trial is an open-label, multi-center, single arm study of Sodium Cridanimod in Patients with Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma. The trial is designed to enroll up to 58 patients in eight countries including Estonia, Belarus, Canada, Czech Republic, Russian Federation, Slovakia, Ukraine and the United States. Important study objectives are to investigate the effect of sodium cridanimod on the levels of progesterone receptor (PrR) in tumor tissue, and how this effect correlates to a patient’s clinical response to progestin therapy.

About Progesterone Receptor Negative Endometrial Carcinoma
Endometrial cancer is the most common gynecologic malignancy and represents a major health concern, because overall five-year survival rates have not improved over the past three decades. A subset of endometrial cancer patients have been identified, whose tumors no longer express PrR, which limits the clinical impact of progestin-based therapy. It is postulated that restoration of PrR expression can re-sensitize endometrial tumors toward progestin, such that patients would become more responsive to progestin therapy.